Comparison of old anti-diabetic drugs Pioglitazone and Glimepiride in Indian patients, which one is better in terms of improvement of underlying cause of disease.
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/09/057166
- Lead Sponsor
- Professor and Head department of Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Newly diagnosed type-2 Diabetes Mellitus (ADA criteria) with BMI <30 kg/m2 and age > 18yrs 2. Type 2 diabetic patients with uncontrolled blood sugar (FBS >130, PPBS >180) on life-style intervention plus maximally tolerated dose of metformin
Exclusion Criteria: 1. Patients with secondary Diabetes. 2. Patients with Type 1 Diabetes Mellitus. 3. Patients with latent autoimmune diabetes of adult. 4. Patient on insulin 5. Contraindication to pioglitazone (Active liver disease, NYHA Class 3 and 4 chf, CSME, hypersensitivity), metformin (severe renal impairment; egfr < 30mL/min/1.73m2, known hypersensitivity, acute or chronic metabolic acidosis including DKA) or glimepiride (known hypersensitivity, DKA, G6PD deficiency) 6. Pregnancy and lactation 7. Who refused for consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method